[{"data": {"name": "FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Nicole J. Gormley", "@type": "Person"}, {"name": "Chia-Wen Ko", "@type": "Person"}, {"name": "Albert Deisseroth", "@type": "Person"}, {"name": "Lei Nie", "@type": "Person"}, {"name": "Edvardas Kaminskas", "@type": "Person"}, {"name": "Natasha Kormanik", "@type": "Person"}, {"name": "Kirsten B. Goldberg", "@type": "Person"}, {"name": "Ann T. Farrell", "@type": "Person"}, {"name": "Richard Pazdur", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://clincancerres.aacrjournals.org/content/clincanres/23/22/6759.full.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "American Association for Cancer Research (AACR)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1158/1078-0432.ccr-16-2870", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCNi7B6jqS6e8-CTC6vfkow3vpd-CDFZxt6BpLse9-CRKK6yNbiAZQB", "propertyID": "ISCC"}], "datePublished": "2017-03-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]